Pharmacoepidemiology in Neurodegenerative Disorders
Prof. Dr. Britta Hänisch
Group Leader
Kurt-Georg-Kiesinger-Allee 3
53175 Bonn

britta.haenisch@dzne.de
 +49 228 99307 5721

Areas of investigation/research focus

Multimorbidity and polypharmacy increase the risk of adverse drug reactions and can accelerate cognitive decline. Therefore, the main goal of the research group is to investigate effects of different drug treatments in view of parameters especially relevant in elderly patients such as cognitive performance, falls, and use of health care services. Drugs that have been approved so far to enhance cognition in dementia patients cannot provide stable disease-modification or cure. Thus, it is highly interesting to detect interventions which are able to prevent or at least delay the onset of cognitive decline and dementia in the elderly population. In this way drug repositioning can also be achieved. The aim is to assess efficiency and safety of pharmacotherapy. Furthermore, risk constellations in view of different treatments with multiple drugs should be detected. Thus, pharmacoepidemiological analyses contribute to drug safety and provide a basis for further decisions in health care policy.

 more Infos

The group is analyzing data from multiple sources, including primary and secondary data. Primary data comprise data from longitudinal cohort studies. Detailed documentation of sociodemographic parameters, cognitive performance, medical history and medication allow comprehensive pharmacoepidemiological analyses. Incidence, progress and predictors of cognitive decline and dementia are identified. Inclusion of data on genetic variability can provide hints for a structured personalized therapy. Other sources of information are claims data from public health insurance, so-called routine data. These data offer pharmacoepidemiological research with large longitudinal samples on a broad population-based level. The evaluation of different kinds of epidemiological databases, including primary and secondary data, allows combining data from applied clinical research and claims data in order to examine the benefit/risk ratio of medicinal products.

Schlüsselpublikationen

Nadine Janis Pohontsch, Kathrin Heser, Antje Löffler, Britta Haenisch, Debora Parker, Tobias Luck, Steffi G. Riedel-Heller, Wolfgang Maier, Frank Jessen, Martin Scherer. General practitioners’ views on (long-term) prescription and use of problematic and potentially inappropriate medication for oldest-old patients - A qualitative interview study with GPs (CIM-TRIAD study). BMC Family Practice. 2017 Feb 16; 18 doi: 10.1186/s12875-017-0595-3
Anna Papazoglou, Julien Soos, Andreas Lundt, Carola Wormuth, Varun Raj Ginde, Ralf Müller, Christina Henseler, Karl Broich, Kan Xie, Dan Ehninger, Britta Haenisch, Marco Weiergräber. Gender-Specific Hippocampal Dysrhythmia and Aberrant Hippocampal and Cortical Excitability in the APPswePS1dE9 Model of Alzheimer's Disease. Neural Plasticity. 2015 Dec 31; 2016 doi: 10.1155/2016/7167358
Willy Gomm, Klaus Von Holt, Friederike Thomé, Karl Broich, Wolfgang Maier, Klaus Weckbecker, Anne Fink, Gabriele Doblhammer, Britta Haenisch. Regular Benzodiazepine and Z-Substance Use and Risk of Dementia: An Analysis of German Claims Data. Journal of Alzheimer's Disease. 2016 Sep 05; 54:801-808. doi: 10.3233/JAD-151006
Gomm W, von Holt K, Thome F, et al. Association of Proton Pump Inhibitors With Risk of Dementia: A Pharmacoepidemiological Claims Data Analysis. JAMA Neurol. 2016 Jan 01; 73:410-416. doi: 10.1001/jamaneurol.2015.4791
Huber, Blumberg, Chatterjee, Haenisch, Schlosser-Weber, Broich. Drug safety: Challenge in an aging society. Nervenarzt. 2014 Nov 11; 85:1352-1362. doi: 10.1007/s00115-014-4088-5

Info-Hotline

Thursdays 1:30-4:30 pm

Patients +49 800-7799001

(free of charge)

Professionals +49 180-779900

(9 Cent/Min. German landline, mobile and out of Germany possibly more expensive)